The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

OBJECTIVE To develop a set of disease activity measures for use in rheumatoid arthritis (RA) clinical trials, as well as to recommend specific methods for assessing each outcome measure. This is not intended to be a restrictive list, but rather, a core set of measures that should be included in all trials. METHODS We evaluated disease activity measures commonly used in RA trials, to determine which measures best met each of 5 types of validity: construct, face, content, criterion, and discriminant. The evaluation consisted of an initial structured review of the literature on the validity of measures, with an analysis of data obtained from clinical trials to fill in gaps in this literature. A committee of experts in clinical trials, health services research, and biostatistics reviewed the validity data. A nominal group process method was used to reach consensus on a core set of disease activity measures. This set was then reviewed and finalized at an international conference on outcome measures for RA clinical trials. The committee also selected specific ways to assess each outcome. RESULTS The core set of disease activity measures consists of a tender joint count, swollen joint count, patient's assessment of pain, patient's and physician's global assessments of disease activity, patient's assessment of physical function, and laboratory evaluation of 1 acute-phase reactant. Together, these measures sample the broad range of improvement in RA (have content validity), and all are at least moderately sensitive to change (have discriminant validity). Many of them predict other important long-term outcomes in RA, including physical disability, radiographic damage, and death. Other disease activity measures frequently used in clinical trials were not chosen for any one of several reasons, including insensitivity to change or duplication of information provided by one of the core measures (e.g., tender joint score and tender joint count). The committee also proposes specific ways of measuring each outcome. CONCLUSION We propose a core set of outcome measures for RA clinical trials. We hope this will decrease the number of outcomes assessed and standardize outcomes assessments. Further, we hope that these measures will be found useful in long-term studies.

[1]  N. Bellamy,et al.  Rheumatoid arthritis antirheumatic drug trials. I. Effects of standardization procedures on observer dependent outcome measures. , 1991, The Journal of rheumatology.

[2]  T. Pincus,et al.  Radiographic and joint count findings of the hand in rheumatoid arthritis. Related and unrelated findings. , 1988, Arthritis and rheumatism.

[3]  R. Meenan,et al.  SENSITIVITY OF A HEALTH STATUS MEASURE TO SHORT‐TERM CLINICAL CHANGES IN ARTHRITIS , 1989, Arthritis and rheumatism.

[4]  F. Wolfe,et al.  The latex test revisited. Rheumatoid factor testing in 8,287 rheumatic disease patients. , 1991, Arthritis and rheumatism.

[5]  J. Fries,et al.  Mortality predictors among 263 patients with rheumatoid arthritis. , 1991, The Journal of rheumatology.

[6]  D. Heijde,et al.  Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. , 1992 .

[7]  M. Guttadauria,et al.  Outcome assessment in clinical trials. Evidence for the sensitivity of a health status measure. , 1984, Arthritis and rheumatism.

[8]  Theodore T. Herbert,et al.  A COMPARISON OF DECISION QUALITY UNDER NOMINAL AND INTERACTING CONSENSUS GROUP FORMATS: THE CASE OF THE STRUCTURED PROBLEM* , 1979 .

[9]  P Tugwell,et al.  The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. , 1987, The Journal of rheumatology.

[10]  Blair Y. Stephenson,et al.  An Empirical Test of the Nominal Group Technique in State Solar Energy Planning , 1982 .

[11]  T. Pincus,et al.  Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. , 1987, The Journal of rheumatology.

[12]  L. Kazis,et al.  Health status as a predictor of mortality in rheumatoid arthritis: a five-year study. , 1990, The Journal of rheumatology.

[13]  P. Dawes,et al.  Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. , 1986, British journal of rheumatology.

[14]  T. Spector,et al.  Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. , 1991, The Journal of rheumatology.

[15]  W. Buchanan,et al.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. , 1968, The Quarterly journal of medicine.

[16]  G. Langley,et al.  Problems associated with pain measurement in arthritis: comparison of the visual analogue and verbal rating scales. , 1984, Clinical and experimental rheumatology.

[17]  L. Chambers,et al.  The McMaster Health Index Questionnaire as a measure of quality of life for patients with rheumatoid disease. , 1982, The Journal of rheumatology.

[18]  C. Bombardier,et al.  Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial. , 1986, The American journal of medicine.

[19]  M. Liang,et al.  The total hip arthroplasty outcome evaluation form of the American Academy of Orthopaedic Surgeons. Results of a nominal group process. The American Academy of Orthopaedic Surgeons Task Force on Outcome Studies. , 1991, The Journal of bone and joint surgery. American volume.

[20]  N. Black,et al.  Can out‐of‐hours work by junior doctors in obstetrics be reduced? , 1992, British journal of obstetrics and gynaecology.

[21]  D. Mainland.  A Seven‐Day variability study of 499 patients with peripheral rheumatoid arthritis , 1965 .

[22]  P. Constable,et al.  What are the 'best' measurements for monitoring patients during short-term second-line therapy? , 1988, British journal of rheumatology.

[23]  J. Fries,et al.  Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. , 1992, Annals of the rheumatic diseases.

[24]  D. L. Scott,et al.  Classification of antirheumatic drugs. A new proposal. , 1992, Arthritis and rheumatism.

[25]  C. Bombardier,et al.  A comparison of health-related quality-of-life measures for rheumatoid arthritis research* , 1991 .

[26]  F. Wolfe,et al.  The assessment and prediction of functional disability in rheumatoid arthritis. , 1991, The Journal of rheumatology.

[27]  P. van Riel,et al.  Sensitivity of a Dutch Health Assessment Questionnaire in a Trial Comparing Hydroxychloroquine vs. Sulphasalazine , 1990 .

[28]  T. Möttönen,et al.  Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. , 1988, Annals of the rheumatic diseases.

[29]  F. Wolfe,et al.  Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis. , 1991, The Journal of rheumatology.

[30]  D. Felson,et al.  Which traditional measures should be used in rheumatoid arthritis clinical trials? , 1989, Arthritis and rheumatism.

[31]  P. Tugwell,et al.  An experiment in reducing interobserver variability of the examination for joint tenderness. , 1988, The Journal of rheumatology.

[32]  T. Spector,et al.  What should we hope to achieve when treating rheumatoid arthritis? , 1989, Annals of the rheumatic diseases.

[33]  J. Fries,et al.  Survival, prognosis, and causes of death in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[34]  Kolodny Al.  Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. , 1988 .

[35]  F. Wolfe,et al.  Sensitivity to change of the health assessment questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. , 1992, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[36]  David H. Gustafson,et al.  Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes , 1976 .

[37]  J Lomas,et al.  The role of evidence in the consensus process. Results from a Canadian consensus exercise. , 1988, JAMA.

[38]  J. Stuart,et al.  EFFICACY OF TESTS USED TO MONITOR RHEUMATOID ARTHRITIS , 1989, The Lancet.

[39]  D. Heijde,et al.  Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. , 1988 .

[40]  P. Tugwell,et al.  A methodologic framework for developing and selecting endpoints in clinical trials. , 1982, The Journal of rheumatology.

[41]  H. Moriya,et al.  Suppression of type II collagen-induced arthritis by monoclonal antibodies. , 1991, Arthritis and rheumatism.

[42]  R. Kane,et al.  What are we measuring? An examination of walk time and grip strength. , 1987, The Journal of rheumatology.

[43]  J. Reading,et al.  Reduced joint count indices in the evaluation of rheumatoid arthritis. , 1985, Arthritis and rheumatism.

[44]  P. Allebeck,et al.  Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate. Eleven-year follow-up of an epidemiological study. , 1981, Scandinavian journal of rheumatology.

[45]  A. van der Heide,et al.  The impact of endpoint measures in rheumatoid arthritis clinical trials. , 1992, Seminars in arthritis and rheumatism.

[46]  Peter C. G∅tzsche.  Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials controlled NSAID trials , 1990 .

[47]  A. V. D. Ven,et al.  The Effectiveness of Nominal, Delphi, and Interacting Group Decision Making Processes , 1974 .

[48]  P. Gertman,et al.  Measuring health status in arthritis. The arthritis impact measurement scales. , 1980, Arthritis and rheumatism.

[49]  M. Guttadauria,et al.  Methotrexate in Rheumatoid Arthritis: Impact on Quality of Life Assessed by Traditional Standard-Item and Individualized Patient Preference Health Status Questionnaires , 1990 .

[50]  T. Pincus,et al.  Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. , 1989, Annals of internal medicine.

[51]  J. Rasker,et al.  Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. , 1981, Annals of the rheumatic diseases.

[52]  P. Bacon,et al.  Anti-rheumatic drugs and joint damage in rheumatoid arthritis. , 1985, The Quarterly journal of medicine.

[53]  T. Pincus,et al.  Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. , 1984, Arthritis and rheumatism.